Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

19.93 -0.95 (-4.53%)
Streaming Delayed Price Updated: 11:27 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2025 Financial Results
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Third Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages 
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment 
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... 
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.